

Comparison of Noninvasive Markers of Fibrosis in Patient Disease

Clinical Gastroenterology and Hepatology

7, 1104-1112

DOI: [10.1016/j.cgh.2009.05.033](https://doi.org/10.1016/j.cgh.2009.05.033)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Reply:. Hepatology, 2009, 50, 2049-2050.	3.6	3
2	Recent advances in nonalcoholic fatty liver disease. Current Opinion in Gastroenterology, 2010, 26, 202-208.	1.0	126
3	Noninvasive tools to assess liver disease. Current Opinion in Gastroenterology, 2010, 26, 227-233.	1.0	16
4	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology, 2010, 51, 454-462.	3.6	1,052
5	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology, 2010, 52, 913-924.	3.6	397
6	Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology, 2010, 10, 67.	0.8	51
7	Nonalcoholic fatty liver disease in children. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 14, 1.	1.3	72
8	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut, 2010, 59, 969-974.	6.1	538
9	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 1265-1269.	6.1	690
10	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut, 2010, 59, 861-866.	6.1	182
11	Pathology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 195-203.	8.2	417
12	The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Annals of Medicine, 2011, 43, 487-494.	1.5	19
14	A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. Clinical Gastroenterology and Hepatology, 2011, 9, 150-155.e1.	2.4	90
15	Comment diagnostiquer de façon non invasive la fibrose au cours de la stéatopathie métabolique?. Medecine Des Maladies Metaboliques, 2011, 5, 60-65.	0.1	0
16	Advances in Pediatric Nonalcoholic Fatty Liver Disease. Pediatric Clinics of North America, 2011, 58, 1375-1392.	0.9	46
17	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113.	2.7	253
19	Nonalcoholic Fatty Liver Disease in Children. Korean Journal of Pediatric Gastroenterology and Nutrition, 2011, 14, 209.	0.2	4
20	Usefulness of combination of platelet count and AST/ALT ratio (PAAR index) for excluding advanced fibrosis in nonalcoholic fatty liver disease. Acta Hepatologica Japonica, 2011, 52, 383-386.	0.0	1

#	ARTICLE	IF	CITATIONS
21	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2011, 57, 19.	0.2	10
22	Factors associated with advanced liver fibrosis in patients with non-alcoholic liver disease. <i>Przeglad Gastroenterologiczny</i> , 2011, 4, 234-242.	0.3	0
23	Bioinformatics-Driven Identification and Examination of Candidate Genes for Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2011, 6, e16542.	1.1	21
24	Nonalcoholic fatty liver disease across ethno-racial groups: Do Asian-American adults represent a new at-risk population?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 501-509.	1.4	25
25	Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 163-172.	1.4	135
26	Biomarkers of liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 802-809.	1.4	83
27	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1536-1543.	1.4	145
28	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 525-540.	1.9	254
29	Nutrient intake in Italian obese patients: Relationships with insulin resistance and markers of non-alcoholic fatty liver disease. <i>Nutrition</i> , 2011, 27, 672-676.	1.1	27
30	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011, 46, 1300-1306.	2.3	108
31	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 291-303.	1.0	119
32	Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis. <i>Hepatology</i> , 2011, 53, 726-736.	3.6	815
33	Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 419-424.	1.7	27
34	Non-alcoholic fatty liver disease: what's new under the microscope?. <i>Gut</i> , 2011, 60, 1152-1158.	6.1	31
35	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 13-32.	1.4	23
36	Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. <i>European Journal of Endocrinology</i> , 2012, 166, 993-1002.	1.9	45
37	Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3709-3716.	1.8	198
38	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.2	292

#	ARTICLE	IF	CITATIONS
39	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-12.	3.8	182
40	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 381-394.	1.6	8
41	Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 700-713.	0.9	405
42	Reply:. <i>Hepatology</i> , 2012, 56, 2005-2006.	3.6	0
43	Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?. <i>Journal of Gastroenterology</i> , 2012, 47, 1238-1247.	2.3	25
44	Acoustic radiation force-based shear stiffness and non-invasive panels of tests in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 56, 740-741.	1.8	3
45	Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. <i>Journal of Digestive Diseases</i> , 2012, 13, 588-595.	0.7	33
46	Can Nash Be Diagnosed, Graded, and Staged Noninvasively?. <i>Clinics in Liver Disease</i> , 2012, 16, 567-585.	1.0	64
47	Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 145-155.	0.4	36
48	Non-High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 651-656.	2.4	37
49	Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. <i>Annals of Hepatology</i> , 2012, 11, 426-439.	0.6	41
50	Nonalcoholic Fatty Liver Disease: A Pathological View. , 0, , .		5
51	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. <i>BMC Gastroenterology</i> , 2012, 12, 2.	0.8	295
52	Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. <i>Journal of Gastroenterology</i> , 2012, 47, 586-595.	2.3	421
53	The association of HIV viral load with indirect markers of liver injury. <i>Journal of Viral Hepatitis</i> , 2012, 19, e202-11.	1.0	24
54	Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. <i>Biomarker Research</i> , 2013, 1, 7.	2.8	71
55	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 850-858.	1.9	6
56	NAFLD Fibrosis Score: Is It Ready for Wider Use in Clinical Practice and for Clinical Trials?. <i>Gastroenterology</i> , 2013, 145, 717-719.	0.6	9

#	ARTICLE	IF	CITATIONS
57	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. <i>Journal of Gastroenterology</i> , 2013, 48, 1051-1060.	2.3	37
58	Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2013, 145, 782-789.e4.	0.6	423
59	Noninvasive evaluation of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 666-675.	8.2	238
60	Biomarkers of Liver Fibrosis. <i>Advances in Clinical Chemistry</i> , 2013, 62, 33-122.	1.8	6
61	Markers in Nonalcoholic Steatohepatitis. <i>Advances in Clinical Chemistry</i> , 2013, 61, 67-125.	1.8	16
62	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. <i>Biomarkers</i> , 2013, 18, 607-613.	0.9	16
63	Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population. <i>American Journal of Gastroenterology</i> , 2013, 108, 1861-1868.	0.2	144
64	Rapid development of systemic insulin resistance with overeating is not accompanied by robust changes in skeletal muscle glucose and lipid metabolism. <i>Applied Physiology, Nutrition and Metabolism</i> , 2013, 38, 512-519.	0.9	17
65	Desâ€œgammaâ€œcarboxy prothrombin identified by <sc>P</sc>â€œ1 and <sc>P</sc>â€œ16 antibodies reflects prognosis for patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 671-677.	1.4	10
67	Allostasis in Nonalcoholic Fatty Liver Disease: Implications for Risk Assessment. <i>Digestive Diseases and Sciences</i> , 2013, 58, 302-308.	1.1	3
68	Laboratoryâ€œbased scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis. <i>Liver International</i> , 2013, 33, 1370-1377.	1.9	18
69	APRI, the FIB-4 score, and Fornâ€œTMs index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1076-1081.	0.8	72
70	Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 719-726.	1.1	33
71	Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans. <i>Clinical Infectious Diseases</i> , 2013, 56, 1498-1504.	2.9	93
72	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , 2013, 66, 1033-1045.	1.0	70
73	Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected nonâ€œalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1267-1277.	1.9	159
74	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 652-658.	0.8	76
75	Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. <i>Hepatology</i> , 2013, 57, 1357-1365.	3.6	614

#	ARTICLE	IF	CITATIONS
76	Association of Hepatitis C With Markers of Hemostasis In HIV-Infected and Uninfected Women in the Women's Interagency HIV Study (WIHS). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 301-310.	0.9	7
77	Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2013, 8, e66328.	1.1	59
78	Clinical Application of Non-Invasive Markers of Liver Fibrosis. , 0, , .		2
79	Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. <i>Annals of Hepatology</i> , 2013, 12, 416-424.	0.6	37
80	Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 8377.	1.4	76
81	Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 607-618.	0.8	122
82	The Clinical Significance of Serum Ferritin in Pediatric Non-Alcoholic Fatty Liver Disease. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2014, 17, 248.	0.4	11
83	Noninvasive Biomarkers of Liver Fibrosis: An Overview. <i>Advances in Hepatology</i> , 2014, 2014, 1-15.	1.3	47
84	Appraisal of Analytes in the Laboratory Panels for Liver Function Tests: Do we Need Aspartate Aminotransferase and Direct Bilirubin in the Panels? Running Head: AST and Direct Bilirubin in Lab Panels. , 2014, 04, .		1
85	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 8393.	1.4	118
86	Non-invasive diagnosis of advanced fibrosis and cirrhosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 16820.	1.4	146
87	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , 2014, 5, 211-218.	0.9	254
88	Non-alcoholic fatty liver disease in patients with diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 503-514.	1.2	0
89	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. <i>Current Pathobiology Reports</i> , 2014, 2, 245-256.	1.6	30
90	Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1163-1169.e1.	2.4	41
91	The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. <i>Clinics in Liver Disease</i> , 2014, 18, 233-248.	1.0	18
92	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 1055-1062.	1.8	85
93	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , 2014, 90, 254-266.	0.9	12

#	ARTICLE	IF	CITATIONS
94	Surgery in Patients with Portal Hypertension. <i>Clinics in Liver Disease</i> , 2014, 18, 477-505.	1.0	28
95	Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 385-406.	1.9	69
96	M30 Does Not Predict the Severity of Hepatosteatosi, Whereas Adiponectin Level Declined With Increase of ALT and the Severity of Hepatic Steatosis. <i>Journal of Clinical Laboratory Analysis</i> , 2014, 28, 381-385.	0.9	3
97	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	1.9	320
98	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 475.	1.4	453
99	Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. <i>Hepatology</i> , 2014, 60, 1920-1928.	3.6	388
100	Future watch: Evolving trends in the management of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2015, 5, 139-141.	1.0	0
101	Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1271-1280.	1.9	125
102	Editorial: triglycerides in chronic liver disease - a marker of disease progression?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 239-239.	1.9	1
103	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	18.1	612
104	Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2015, 54, 127-132.	0.3	12
105	Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C. <i>The Cochrane Library</i> , 0, , .	1.5	2
106	Value of fetuin-A as a predictor of liver fibrosis in patients with nonalcoholic fatty liver disease. Author's reply. <i>Liver International</i> , 2015, 35, 2062-2062.	1.9	1
107	Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. <i>Journal of Hypertension</i> , 2015, 33, 1207-1214.	0.3	90
108	Prevalence and Incidence of Liver Dysfunction and Assessment of Biomarkers of Liver Disease in HIV-Infected Asian Children. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e153-e158.	1.1	10
109	Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. <i>Aids</i> , 2015, 29, 2297-2302.	1.0	42
110	Impact of serum glycosylated <i>Wisteria floribunda</i> agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 1083-1090.	1.8	35
111	A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. <i>Hepatology</i> , 2015, 62, 1433-1443.	3.6	61

#	ARTICLE	IF	CITATIONS
112	Low fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 106-116.	1.9	21
113	Liver fibrosis markers of nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2015, 21, 7427.	1.4	55
114	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
115	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. <i>World Journal of Gastroenterology</i> , 2015, 21, 11077.	1.4	132
116	Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. <i>International Journal of Molecular Sciences</i> , 2015, 16, 25552-25559.	1.8	26
117	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	1.1	7
118	Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects. <i>PLoS ONE</i> , 2015, 10, e0132640.	1.1	63
119	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	41
120	Non-Alcoholic Fatty Liver Disease in Patients with Diabetes Mellitus: A Clinician's Perspective. <i>International Journal of Digestive Diseases</i> , 2015, 01, .	0.2	5
121	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. <i>Journal of Hepatology</i> , 2015, 63, 237-264.	1.8	1,463
122	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1039-1053.	1.4	13
123	Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?. <i>Current Hepatology Reports</i> , 2015, 14, 109-118.	0.4	19
124	<i>Helicobacter pylori</i> infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2015, 50, 996-1004.	2.3	62
126	Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 1-9.	0.4	69
127	Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 777-783.	1.0	13
128	New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. <i>Hepatology International</i> , 2015, 9, 269-277.	1.9	8
129	FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1311-1319.	1.2	11
130	Non-alcoholic fatty liver disease in 2015. <i>World Journal of Hepatology</i> , 2015, 7, 1450.	0.8	160

#	ARTICLE	IF	CITATIONS
131	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms. <i>Current Diabetes Reports</i> , 2015, 15, 607.	1.7	102
132	Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation. <i>Journal of Gastroenterology</i> , 2015, 50, 1206-1213.	2.3	90
133	Noninvasive Markers of Fibrosis in the Assessment of Cirrhosis. , 2015, , 39-47.		0
134	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 137-141.	0.8	36
135	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 291-303.	1.8	65
136	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. <i>Journal of Hepatology</i> , 2015, 62, 1148-1155.	1.8	840
137	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. <i>Drugs</i> , 2015, 75, 1373-1392.	4.9	61
138	Nonalcoholic fatty liver disease – current status and future directions. <i>Journal of Digestive Diseases</i> , 2015, 16, 541-557.	0.7	80
139	Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. <i>Indian Journal of Gastroenterology</i> , 2015, 34, 281-285.	0.7	12
140	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573.	1.9	116
141	Contemporary Assessment of Hepatic Fibrosis. <i>Clinics in Liver Disease</i> , 2015, 19, 123-134.	1.0	25
142	A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-12.	0.5	10
143	Effect of Alkaloids from <i>Nelumbinis Plumula</i> against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	9
144	NAFLD and Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 562.	1.8	142
145	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	1.1	62
146	The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. <i>PLoS ONE</i> , 2016, 11, e0157517.	1.1	25
147	Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0158066.	1.1	12
149	Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. <i>Frontiers in Pharmacology</i> , 2016, 7, 159.	1.6	67

#	ARTICLE	IF	CITATIONS
150	Performance of noninvasive models of fibrosis in predicting mild to moderate fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579.	1.9	38
151	FIB-4 Index is a Predictor of Background Liver Fibrosis and Long-Term Outcomes After Curative Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 467-474.	0.7	23
152	Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 734-743.	1.9	74
153	Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus. <i>Journal of Diabetes</i> , 2016, 8, 640-646.	0.8	17
154	Association of coronary artery calcification with liver fibrosis in Japanese patients with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2016, 46, 1107-1117.	1.8	17
156	Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1937-1944.	0.9	83
158	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	3.7	131
159	Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1356-1364.	1.1	117
160	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1214-1225.	1.1	130
161	Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. <i>Current Hepatology Reports</i> , 2016, 15, 117-124.	0.4	1
162	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 86-95.	0.4	23
163	Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1790-1792.	1.1	2
164	Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. <i>Current HIV/AIDS Reports</i> , 2016, 13, 279-288.	1.1	11
165	Obesity, NASH, and HCC. , 2016, , 275-286.		0
166	The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. <i>Endocrine Journal</i> , 2016, 63, 877-884.	0.7	57
167	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. <i>Hepatology</i> , 2016, 64, 2028-2037.	3.6	78
168	Targeting Hepatic Fibrosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3118-3139.	1.1	28
169	Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. <i>Oncology</i> , 2016, 91, 341-347.	0.9	24

#	ARTICLE	IF	CITATIONS
170	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , 2016, 30, 2635-2643.	1.0	78
171	The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease. <i>Nutrition and Diabetes</i> , 2016, 6, e210-e210.	1.5	20
172	Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. <i>Hepatology Research</i> , 2016, 46, 862-870.	1.8	165
173	Alcoholic and Non-Alcoholic Fatty Liver Disease. , 2016, , .		5
174	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1811-1822.e4.	0.6	93
175	Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 986-994.	0.2	160
176	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 277-292.	1.0	32
177	Diagnostic Considerations and Clinical End Points for Nonalcoholic Steatohepatitis. , 2016, , 211-221.		0
178	Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1087-1095.	1.5	53
179	The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 195-203.	0.8	11
180	Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 597-605.	2.4	26
182	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. <i>Journal of Gastroenterology</i> , 2016, 51, 380-389.	2.3	18
183	Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 451-458.	1.4	16
184	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. <i>Obesity Surgery</i> , 2017, 27, 115-125.	1.1	30
185	HÃgado graso no alcohÃlico y diabetes. <i>Medicina ClÃnica</i> , 2017, 148, 33-38.	0.3	3
186	Dual-photon microscopy-based quantitation of fibrosis-related parameters (qâFP) to model disease progression in steatohepatitis. <i>Hepatology</i> , 2017, 65, 1891-1903.	3.6	43
187	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.4	254
188	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	4.3	256

#	ARTICLE	IF	CITATIONS
189	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	2.4	42
190	Liver fibrosis scores predict liver disease mortality in the United States population. <i>Hepatology</i> , 2017, 66, 84-95.	3.6	158
191	Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. <i>American Journal of Gastroenterology</i> , 2017, 112, 581-587.	0.2	178
192	Treatment of NASH: What Helps Beyond Weight Loss?. <i>American Journal of Gastroenterology</i> , 2017, 112, 821-824.	0.2	4
193	Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. <i>Scientific Reports</i> , 2017, 7, 46458.	1.6	9
194	AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2017, 49, 1133-1138.	0.4	49
195	Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. <i>Oncology</i> , 2017, 93, 92-98.	0.9	44
196	Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 150-155.	0.9	17
197	High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1355-1358.	2.4	13
198	The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. <i>Diabetology International</i> , 2017, 8, 218-227.	0.7	23
199	Hemostatic and Non-hemostatic Functions of Platelets in Patients with Liver Disease. , 2017, , 1169-1181.		2
200	Non-alcoholic fatty liver disease and diabetes. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 33-38.	0.1	1
201	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.4	8
202	Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. <i>Growth Hormone and IGF Research</i> , 2017, 37, 1-6.	0.5	7
203	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000158.	1.1	3
204	Use of Liver Imaging and Biopsy in Clinical Practice. <i>New England Journal of Medicine</i> , 2017, 377, 756-768.	13.9	280
205	Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. <i>Hepatology Communications</i> , 2017, 1, 780-791.	2.0	38
206	Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. <i>Diabetes Care</i> , 2017, 40, 1364-1372.	4.3	216

#	ARTICLE	IF	CITATIONS
207	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	1.9	134
208	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 308-316.	0.4	0
209	Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease. <i>JGH Open</i> , 2017, 1, 112-119.	0.7	13
210	Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. <i>Open Heart</i> , 2017, 4, e000598.	0.9	72
211	Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2017, 11, 115-124.	1.9	9
212	Nonobese Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 474-485.	2.4	262
213	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
214	Performance of the Bard Scoring System in Bariatric Surgery Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2017, 27, 394-398.	1.1	9
216	Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 276-281.	0.3	26
217	Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver Disease. , 2017, , .		3
218	New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2017, 56, 1459-1465.	0.3	2
219	Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 859.	1.4	51
220	Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2017, 23, 7425-7432.	1.4	33
221	Treat-to-Target in Autoimmune Hepatitis: How Far To Go?. <i>Journal of AIDS & Clinical Research</i> , 2017, 8, .	0.5	0
222	Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2998.	1.7	7
223	Editorial: the impact of steatosis on liver stiffness quantification is minimal. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1416-1417.	1.9	1
224	Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 1285-1291.	2.3	24
225	Nonalcoholic fatty liver disease is associated with decreased lung function. <i>Liver International</i> , 2018, 38, 2091-2100.	1.9	25

#	ARTICLE	IF	CITATIONS
226	Screening for therapeutic trials and treatment indication in clinical practice: <sc>MACK</sc>, a new blood test for the diagnosis of fibrotic <sc>NASH</sc>. Alimentary Pharmacology and Therapeutics, 2018, 47, 1387-1396.	1.9	55
227	Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver International, 2018, 38, 1793-1802.	1.9	79
228	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 58-68.	2.0	42
229	Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men. Clinical Gastroenterology and Hepatology, 2018, 16, 1131-1137.e5.	2.4	42
230	Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. Journal of the Formosan Medical Association, 2018, 117, 1011-1018.	0.8	9
231	Current and future pharmacological therapies for NAFLD/NASH. Journal of Gastroenterology, 2018, 53, 362-376.	2.3	490
232	New scoring system combining the FIB-4 index and cytokeatin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers, 2018, 23, 328-334.	0.9	20
233	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
235	Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 1702-1709.	2.2	39
236	A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. Journal of Gastroenterology, 2018, 53, 129-139.	2.3	45
237	Usefulness of the index of <sc>NASH</sc> " <sc>ION</sc> for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	1.9	22
238	Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year community study. Hepatology, 2018, 67, 1726-1736.	3.6	239
239	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 918-925.	1.4	29
240	Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. Journal of Medical Virology, 2018, 90, 313-319.	2.5	51
241	Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabetic Medicine, 2018, 35, 89-98.	1.2	35
242	Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients. Diabetes Research and Clinical Practice, 2018, 135, 65-72.	1.1	21
243	Non-obese fatty liver disease is associated with lacunar infarct. Liver International, 2018, 38, 1292-1299.	1.9	13
245	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of Hepatology, 2018, 68, 305-315.	1.8	427

#	ARTICLE	IF	CITATIONS
246	Pharmacotherapy for NASH: Current and emerging. <i>Journal of Hepatology</i> , 2018, 68, 362-375.	1.8	249
247	Systematic review and meta-analysis: noninvasive detection of nonalcoholic fatty liver disease related fibrosis in the obese. <i>Obesity Reviews</i> , 2018, 19, 281-294.	3.1	22
248	Determinants of fibrosis progression and regression in NASH. <i>Journal of Hepatology</i> , 2018, 68, 238-250.	1.8	350
249	Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2018, 45, 243-249.	0.6	36
250	Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 331-341.	1.9	41
251	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	3.6	296
252	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.	3.6	1,474
253	A practical clinical approach to liver fibrosis. <i>Singapore Medical Journal</i> , 2018, 59, 628-633.	0.3	14
254	Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 64-74.	0.7	73
255	Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 458.	1.0	23
256	Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function. <i>Scientific Reports</i> , 2018, 8, 17757.	1.6	26
257	Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0207479.	1.1	3
258	The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease. <i>Journal of Medicine and Life</i> , 2018, 11, 243-246.	0.4	6
259	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1828-1837.e2.	0.6	490
260	Serum Autotaxin Concentrations Reflect Changes in Liver Stiffness and Fibrosis After Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Hepatology Communications</i> , 2018, 2, 1111-1122.	2.0	9
261	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
262	Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3498-3508.	1.1	12
263	Fatty Liver Disease in Children and Adolescents with Type 1 Diabetes Mellitus(Clinical and Diagnostic) Tj ETQq1 1 0,784314 rgBT /Over	0,2	

#	ARTICLE	IF	CITATIONS
264	Leucocyte telomere shortening is associated with nonalcoholic fatty liver disease-related advanced fibrosis. <i>Liver International</i> , 2018, 38, 1839-1848.	1.9	24
265	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2259-2266.	1.1	26
266	Speculation of the Time-Dependent Change of FIB4 Index in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	5
267	Fatty Liver Disease. , 2018, , 308-371.		14
268	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. <i>BMJ: British Medical Journal</i> , 2018, 362, k2734.	2.4	81
269	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	2.3	68
270	Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-10.	0.8	18
271	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 130.	2.3	177
272	Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0202393.	1.1	27
273	Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 219.	1.0	28
274	An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. <i>Scientific Reports</i> , 2018, 8, 12414.	1.6	53
275	Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , 2018, 13, e0191985.	1.1	33
276	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 509-517.	3.7	106
277	The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection. <i>British Journal of Biomedical Science</i> , 2018, 75, 128-132.	1.2	20
278	Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 94-103.	1.1	38
279	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 124-133.	0.9	60
280	Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with nonalcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). <i>Hepatology Research</i> , 2019, 49, 64-71.	1.8	85
281	Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. <i>Hepatology</i> , 2019, 70, 511-521.	3.6	95

#	ARTICLE	IF	CITATIONS
282	Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 207-214.	1.4	30
283	Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Hepatology</i> , 2019, 69, 64-75.	3.6	107
284	Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. <i>Journal of Gastroenterology</i> , 2019, 54, 64-77.	2.3	21
285	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	3.6	174
286	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2301-2308.	1.9	15
287	Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States. <i>Journal of Dental Research</i> , 2019, 98, 1219-1226.	2.5	33
288	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease—Targeting Primary Care Physicians. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 611-618.	2.4	1
289	Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. <i>Hepatology Research</i> , 2019, 49, 1441-1450.	1.8	11
290	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177.	0.3	18
291	Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. <i>PLoS ONE</i> , 2019, 14, e0217263.	1.1	15
292	Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). <i>Clinical Endocrinology</i> , 2019, 91, 544-552.	1.2	24
293	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2570-2580.e37.	2.4	75
294	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 590-598.	1.9	62
295	Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. <i>Journal of Clinical Medicine</i> , 2019, 8, 1057.	1.0	14
296	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
297	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1348-1351.	4.3	37
298	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
299	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. <i>Pharmaceutical Medicine</i> , 2019, 33, 451-463.	1.0	12

#	ARTICLE	IF	CITATIONS
300	Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 89-97.	0.6	1
301	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1113-1123.	1.6	55
302	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. <i>Gene Expression</i> , 2019, 19, 187-198.	0.5	23
303	Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. <i>JHEP Reports</i> , 2019, 1, 429-437.	2.6	31
304	Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116524.	0.3	28
305	SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. <i>World Journal of Diabetes</i> , 2019, 10, 114-132.	1.3	60
306	Efficacy of repeat doses of avatrombopag: a case series. <i>Digestive Medicine Research</i> , 0, 2, 9-9.	0.2	4
307	Significant decrease in <i>Faecalibacterium</i> among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. <i>Hepatology International</i> , 2019, 13, 748-756.	1.9	46
308	The Fibrosis-4 Index Is Useful for Predicting Mortality in Patients with Pulmonary Hypertension due to Left Heart Disease. <i>International Heart Journal</i> , 2019, 60, 1147-1153.	0.5	7
309	Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3570.	1.2	29
310	The Utility of Noninvasive Scoring Systems for Prediction of Hepatic Steatosis in Liver Transplantation Donor Candidates. <i>Transplantation Proceedings</i> , 2019, 51, 2383-2386.	0.3	2
311	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
312	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016. <i>Hepatology International</i> , 2019, 13, 205-213.	1.9	63
313	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1626-1632.	1.4	19
314	Consenso mexicano de la enfermedad por hígado graso no alcohólico. <i>Revista De Gastroenterología De México</i> , 2019, 84, 69-99.	0.4	26
315	<p>Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 937-945.	1.1	5
316	Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2019, 98, e14139.	0.4	15
317	Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000288.	1.1	20

#	ARTICLE	IF	CITATIONS
318	Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1884-1894.	1.9	31
319	A Simple Index for Nonalcoholic Steatohepatitis "HUIFA" Based on Routinely Performed Blood Tests. <i>Medicina (Lithuania)</i> , 2019, 55, 243.	0.8	8
320	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2776-2784.e4.	2.4	108
321	Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. <i>Hormones</i> , 2019, 18, 255-265.	0.9	6
322	Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1331-1338.	1.1	10
323	High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. <i>Endocrine Journal</i> , 2019, 66, 637-645.	0.7	14
324	Liver Fibrosis Determination. <i>Gastroenterology Clinics of North America</i> , 2019, 48, 281-289.	1.0	55
325	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	0.9	70
327	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1948.	1.8	127
328	Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2019, 39, 631-641.	1.1	21
329	Emerging Circulating Biomarkers for the Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
330	Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). <i>Annals of Hepatology</i> , 2019, 18, 445-449.	0.6	20
331	Past, present and future perspectives in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 377-386.	8.2	357
332	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 41.	0.7	80
333	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1867-1876.e3.	2.4	31
334	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	2.4	145
335	Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 328-334.	0.6	55
336	Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?. <i>Journal of Gastroenterology</i> , 2019, 54, 474-475.	2.3	0

#	ARTICLE	IF	CITATIONS
337	Non-invasive assessment of NAFLD as systemic disease—A machine learning perspective. PLoS ONE, 2019, 14, e0214436.	1.1	56
338	High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart and Vessels, 2019, 34, 1559-1569.	0.5	2
339	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1829-1835.	1.4	18
340	Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver International, 2019, 39, 1343-1354.	1.9	18
341	Effects of sleeve gastrectomy on liver enzymes, non-alcoholic fatty liver disease-related fibrosis and steatosis scores in morbidly obese patients: first year follow-up. Journal of Laboratory Medicine, 2019, 43, 115-122.	1.1	6
342	The Mexican consensus on nonalcoholic fatty liver disease. Revista De Gastroenterología De México (English Edition), 2019, 84, 69-99.	0.1	6
343	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. Cancers, 2019, 11, 425.	1.7	8
344	Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 489-495.	1.1	24
345	Fibrosis-4 index predicts mortality in HIV/HCV co-infected patients receiving combination antiretroviral therapy in rural China. BioScience Trends, 2019, 13, 32-39.	1.1	4
346	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. Cancers, 2019, 11, 203.	1.7	6
347	Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882325.	0.6	3
348	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Scientific Reports, 2019, 9, 1814.	1.6	21
349	Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Drug Safety, 2019, 42, 701-711.	1.4	19
351	Diagnostic Performance of Serum Asialo- α 1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 74, 341.	0.2	6
352	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. Oncologist, 2019, 24, e653-e661.	1.9	16
353	Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. American Journal of Gastroenterology, 2019, 114, 620-629.	0.2	52
354	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e86-e94.	0.9	53
355	Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Scientific Reports, 2019, 9, 18856.	1.6	26

#	ARTICLE	IF	CITATIONS
356	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.2	65
357	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	5.5	566
358	Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 543-550.e2.	2.4	56
359	High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 191-200.	1.1	17
360	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.	2.9	14
361	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. <i>Advanced Science</i> , 2019, 6, 1801585.	5.6	110
362	Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019, 39, 748-757.	1.9	46
363	Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. <i>Gut</i> , 2019, 68, 1667-1675.	6.1	130
364	Adult Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 23-46.		0
365	Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1004-1011.	1.1	69
366	Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 2414-2426.	3.6	162
367	Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 453-463.	0.2	84
368	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.	1.9	38
369	Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 296-303.	1.8	29
370	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019, 67, 303-311.	0.7	59
371	Pegbelfermin (BMS986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. <i>Obesity</i> , 2019, 27, 41-49.	1.5	180
372	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1411-1416.	1.4	6
373	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , 2019, 131, 19-30.	0.9	4

#	ARTICLE	IF	CITATIONS
374	Relationship between three commonly used noninvasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	1.9	47
375	Albumin-Indocyanine Green Evaluation Grading System Predicts Post-Hepatectomy Liver Failure for Biliary Tract Cancer. <i>Digestive Surgery</i> , 2019, 36, 13-19.	0.6	10
376	Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 100-112.	2.3	18
377	Fibrosis-4 index reflects right-sided filling pressure in patients with heart failure. <i>Heart and Vessels</i> , 2020, 35, 376-383.	0.5	21
378	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 710-718.e4.	2.4	10
379	Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 356-362.	2.7	10
380	Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2158-2167.	2.4	9
381	NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 88-98.	0.4	15
382	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
383	Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 205-215.e7.	2.4	8
384	Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 861-873.	3.6	49
385	Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 349-355.	0.7	3
386	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 808-819.	3.6	170
387	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 393-403.	2.2	53
388	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	1.0	12
389	Nonalcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 833-839.	1.4	66
390	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 45-62.	1.0	5
391	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1917-1925.	0.9	11

#	ARTICLE	IF	CITATIONS
392	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events—Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2324-2331.e4.	2.4	136
393	Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 420-425.	0.8	22
394	Liver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage. <i>Stroke</i> , 2020, 51, 830-837.	1.0	41
395	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 642-649.	0.8	24
396	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	2.9	11
397	Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time?. <i>Gastroenterology</i> , 2020, 158, 40-42.	0.6	5
398	Liver stiffness measurement predicts long-term survival and complications in nonalcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	1.9	75
399	Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154026.	1.5	18
400	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 59-66.	0.5	17
401	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
402	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2020, 57, 613-618.	1.2	41
403	Noninvasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , 2020, 40, 894-904.	1.9	19
404	Associations between <i>Helicobacter pylori</i> with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. <i>Helicobacter</i> , 2020, 25, e12756.	1.6	16
405	Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. <i>Advances in Therapy</i> , 2020, 37, 4866-4876.	1.3	4
406	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
407	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. <i>BMC Medicine</i> , 2020, 18, 261.	2.3	66
408	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. <i>Annals of Hepatology</i> , 2020, 19, 622-626.	0.6	23
410	Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. <i>Nutrients</i> , 2020, 12, 2151.	1.7	6

#	ARTICLE	IF	CITATIONS
411	Fibrosis-4 Index, a Noninvasive Fibrosis Marker, Predicts Survival Outcomes After Hepatectomy for Colorectal Cancer Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3534-3541.	0.7	7
412	Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. <i>Diabetes Therapy</i> , 2020, 11, 1849-1860.	1.2	9
413	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00127.	1.0	15
414	Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients. <i>JGH Open</i> , 2020, 4, 929-936.	0.7	5
415	Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101528.	0.7	9
416	Depressive symptoms and risk of liver-related mortality in individuals with hepatitis B virus infection: a cohort study. <i>Scientific Reports</i> , 2020, 10, 20812.	1.6	7
417	Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2233-2239.	1.8	9
418	Multiparametric MR mapping in clinical decision-making for diffuse liver disease. <i>Abdominal Radiology</i> , 2020, 45, 3507-3522.	1.0	30
419	External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2387-2393.	1.1	8
420	Abnormal and Euthyroid Ranges of Thyroid Hormones in Serum and Liver Cancer Mortality: A Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2002-2009.	1.1	4
421	Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. <i>Alcohol</i> , 2020, 89, 1-7.	0.8	15
423	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	1.3	21
424	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 511-520.	0.6	20
425	Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2020, 10, 18323.	1.6	21
426	The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. <i>Diagnostics</i> , 2020, 10, 842.	1.3	2
427	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Mono-infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2184-e2193.	2.9	14
428	Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. <i>JGH Open</i> , 2020, 4, 995-1001.	0.7	7
429	Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. <i>Scientific Reports</i> , 2020, 10, 12440.	1.6	37

#	ARTICLE	IF	CITATIONS
430	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. <i>PLoS ONE</i> , 2020, 15, e0237430.	1.1	15
431	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020, 10, 198.	1.1	11
432	The Fibrosis-4 Index Is Associated With Need for Mechanical Ventilation and 30-Day Mortality in Patients Admitted With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2020, 222, 1794-1797.	1.9	29
433	Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1329-1338.	1.1	5
434	Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study. <i>Life</i> , 2020, 10, 175.	1.1	3
435	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	1.0	7
436	Assessment of Liver Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate. <i>Internal Medicine Journal</i> , 2020, , .	0.5	5
437	The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	3
438	Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00165.	1.3	4
439	Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients. <i>Annals of Translational Medicine</i> , 2020, 8, 308-308.	0.7	8
440	Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward". <i>Journal of Hepatology</i> , 2020, 73, 466-467.	1.8	0
441	Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. <i>Annals of Hepatology</i> , 2020, 19, 367-372.	0.6	5
442	Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. <i>Seminars in Liver Disease</i> , 2020, 40, 331-338.	1.8	13
443	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 9.	1.3	60
444	Liver fibrosis associated with potential vinyl chloride and ethylene dichloride exposure from the petrochemical industry. <i>Science of the Total Environment</i> , 2020, 739, 139920.	3.9	5
445	Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. <i>Frontiers in Physiology</i> , 2020, 11, 551.	1.3	5
446	A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 546-552.	0.3	17
447	Association between liver fibrosis and cognition in a nationally representative sample of older adults. <i>European Journal of Neurology</i> , 2020, 27, 1895-1903.	1.7	16

#	ARTICLE	IF	CITATIONS
448	Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study. <i>Nutrients</i> , 2020, 12, 1770.	1.7	11
449	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 726-733.	1.9	43
450	Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. <i>Liver International</i> , 2020, 40, 2139-2147.	1.9	25
451	Gender differences in liver fibrosis among patients younger than 50 years: A retrospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 733-738.	0.7	5
452	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. <i>Journal of Internal Medicine</i> , 2020, 287, 711-722.	2.7	50
453	Association of novel markers of liver disease with neonatal liver disease in premature baboons, <i>Papio sp.</i> . <i>PLoS ONE</i> , 2020, 15, e0228985.	1.1	0
454	Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. <i>Obesity Surgery</i> , 2020, 30, 2538-2546.	1.1	13
455	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
456	Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1175.	3.8	784
457	Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease. <i>Hepatology Research</i> , 2020, 50, 853-862.	1.8	24
458	The risk factors for hepatic steatosis in patients with primary aldosteronism. <i>Endocrine Journal</i> , 2020, 67, 623-629.	0.7	5
459	Association between growth hormone and hypertension in a general population. <i>Hypertension Research</i> , 2020, 43, 1430-1436.	1.5	3
460	Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1232-1241.	2.9	29
461	The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2020, 62, 126601.	1.5	35
462	Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4189.	1.8	26
463	Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4337.	1.8	21
464	Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. <i>Liver International</i> , 2020, 40, 2252-2262.	1.9	14
465	Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. <i>Hepatology Communications</i> , 2020, 4, 998-1011.	2.0	7

#	ARTICLE	IF	CITATIONS
466	Noninvasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. <i>Liver International</i> , 2020, 40, 1303-1315.	1.9	9
467	Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 584.	1.0	27
468	Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. <i>Hepatology Communications</i> , 2020, 4, 518-526.	2.0	12
469	NAFLD and NASH. , 2020, , .		1
470	Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 50.	0.8	8
471	Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 19-19.	1.5	53
472	Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 123-140.	1.0	2
473	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
474	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2020, 10, 321.	1.6	21
475	Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross-sectional study in Korea. <i>Geriatrics and Gerontology International</i> , 2020, 20, 271-276.	0.7	17
476	Collagen biology and noninvasive biomarkers of liver fibrosis. <i>Liver International</i> , 2020, 40, 736-750.	1.9	107
477	Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. <i>Scientific Reports</i> , 2020, 10, 481.	1.6	25
478	Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2073-2080.e7.	2.4	29
479	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, 88.	0.8	25
480	FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, 216-217.	1.8	26
481	Noninvasive Diagnosis of NAFLD and NASH. <i>Cells</i> , 2020, 9, 1005.	1.8	145
482	The <i>PNPLA3</i> rs738409 GC genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1160-1168.	1.9	17
483	Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1636-1643.	1.4	13

#	ARTICLE	IF	CITATIONS
484	Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-8.	1.4	0
485	Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. <i>Atherosclerosis</i> , 2020, 299, 45-52.	0.4	40
486	Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3358.	1.7	27
487	Impact of predictive value of Fibrosis-4 index in patients hospitalized for acute heart failure. <i>International Journal of Cardiology</i> , 2021, 324, 90-95.	0.8	18
488	The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. <i>American Journal of Medicine</i> , 2021, 134, 23-29.	0.6	14
489	A noninvasive index to predict liver cirrhosis in biliary atresia. <i>Pediatric Radiology</i> , 2021, 51, 257-264.	1.1	4
490	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021, 5, 559-572.	2.0	25
491	Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. <i>International Journal of Clinical Practice</i> , 2021, 75, e13770.	0.8	6
492	Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. <i>Hepatology Communications</i> , 2021, 5, 434-445.	2.0	38
493	A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. <i>Modern Pathology</i> , 2021, 34, 808-822.	2.9	29
494	Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. <i>Journal of Viral Hepatitis</i> , 2021, 28, 484-492.	1.0	13
495	Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. <i>Hepatology Communications</i> , 2021, 5, 158-167.	2.0	41
496	FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients. <i>Diabetology International</i> , 2021, 12, 118-125.	0.7	9
497	Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 62-68.	1.8	9
498	Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 979-988.	1.8	28
500	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4046-4057.	1.1	3
501	Lean NAFLD: an underrecognized and challenging disorder in medicine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 351-366.	2.6	40
502	Non-invasive markers of liver fibrosis and outcome in large vessel occlusion stroke. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110372.	1.5	19

#	ARTICLE	IF	CITATIONS
503	Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. <i>Liver International</i> , 2021, 41, 505-514.	1.9	25
504	Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. <i>Annals of Medicine</i> , 2021, 53, 1067-1075.	1.5	11
505	A nutritional intervention that promotes increased vegetable intake in Japanese with non-alcoholic fatty liver disease: a six-month trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 46-53.	0.6	2
506	Prognostic value of impaired hepato-renal function and liver fibrosis in patients admitted for acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1274-1283.	1.4	12
507	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , 2021, 11, 132.	1.3	18
508	Texture Analysis of Gray-Scale Ultrasound Images for Staging of Hepatic Fibrosis. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 116.	0.1	3
509	Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e23.	1.8	30
510	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 261-273.	2.3	28
511	Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 44-57.	4.5	38
512	Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. <i>Hepatology Communications</i> , 2021, 5, 1009-1020.	2.0	20
513	Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab076.	0.4	3
514	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <i>Liver International</i> , 2021, 41, 731-742.	1.9	27
515	Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 3768.	1.6	11
516	Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2021, 10, 239.	2.2	3
517	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021, 31, 2002-2010.	1.1	14
518	Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
519	Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	9
520	Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e368-e374.	0.8	19

#	ARTICLE	IF	CITATIONS
521	Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 292-298.	1.0	10
522	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021, 11, 143.	1.1	22
523	The Association Between Different Obesity Phenotypes and Liver Fibrosis Scores in Elderly Individuals with Fatty Liver in Taiwan. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1473-1483.	1.1	3
524	Decision Tree for the Performance of Intraoperative Liver Biopsy During Bariatric Surgery. <i>Obesity Surgery</i> , 2021, 31, 2641-2648.	1.1	2
525	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinical Therapeutics</i> , 2021, 43, 455-472.	1.1	8
526	Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <i>Liver International</i> , 2021, 41, 1556-1564.	1.9	16
527	Identifying Advanced Fibrosis in NAFLD Using Noninvasive Tests. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	2
528	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1379-1388.	1.1	9
529	Fatty Acid-Binding Protein 1 as a Potential New Serological Marker of Liver Status in Children With Wilson Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 455-462.	0.9	1
530	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 199-208.	0.1	3
531	Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	11
532	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	1.4	5
533	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 181-186.	0.6	13
534	Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1610-1619.	0.4	8
535	Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. <i>Liver International</i> , 2021, 41, 1832-1840.	1.9	35
536	Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. <i>PLoS ONE</i> , 2021, 16, e0249556.	1.1	5
537	Controlled Attenuation Parameter in Healthy Individuals Aged 8-70 Years. <i>Ultrasound International Open</i> , 2021, 07, E6-E13.	0.3	1
538	Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2021, .	0.2	4

#	ARTICLE	IF	CITATIONS
539	A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2021, 21, 144.	0.8	35
540	Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus coinfected patients treated by all-oral direct-acting antivirals. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 465-471.	0.6	5
541	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. <i>Minerva Surgery</i> , 2021, 76, 450-466.	0.1	2
542	Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 822-834.	0.7	7
543	Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e583-e599.	2.4	9
544	Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 1595-1606.	0.1	9
545	Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4416.	1.8	18
546	The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. <i>Hepatology International</i> , 2021, 15, 223-257.	1.9	37
547	Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome. <i>Diagnostics</i> , 2021, 11, 797.	1.3	9
548	Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study. <i>Eating and Weight Disorders</i> , 2021, , 1.	1.2	6
549	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e529-e534.	0.8	14
550	Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. <i>Diagnostics</i> , 2021, 11, 689.	1.3	20
551	Advanced liver fibrosis and the metabolic syndrome in a primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3452.	1.7	10
552	Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G439-G449.	1.6	18
553	Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 524-534.	0.9	10
554	The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. <i>Cancers</i> , 2021, 13, 2301.	1.7	12
555	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
556	Psoriasis and Liver Damage in HIV-Infected Patients. <i>Cells</i> , 2021, 10, 1099.	1.8	1

#	ARTICLE	IF	CITATIONS
557	Periodontitis is associated with increased liver fibrosis in a population-based cohort of US adults. <i>GastroHep</i> , 2021, 3, 179-184.	0.3	1
558	Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2021, 13, 571-583.	0.8	6
559	Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107879.	1.2	10
560	Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box. <i>Hepatology</i> , 2021, 73, 2095-2098.	3.6	4
561	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
562	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	3
563	Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. <i>Obesity Science and Practice</i> , 2021, 7, 497-508.	1.0	2
564	Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 243-245.	0.6	2
565	RE: Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity—an observational study. <i>Eating and Weight Disorders</i> , 2021, , 1.	1.2	1
566	Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults. <i>American Journal of Gastroenterology</i> , 2021, 116, 2270-2278.	0.2	5
567	High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 11753.	1.6	14
568	FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis—Validation in an Indian Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 440-447.	0.4	9
569	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	1.9	19
570	Excessive alcohol intake and liver fibrosis are associated with skeletal muscle mass reduction in elderly men: the Wakayama study. <i>Aging Clinical and Experimental Research</i> , 2021, , 1.	1.4	1
571	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154770.	1.5	101
572	Reply to letter: RE: Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study. <i>Eating and Weight Disorders</i> , 2021, , 1.	1.2	3
573	Pediatric nonalcoholic fatty liver disease—a changing diagnostic paradigm. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 61, 1023-1031.	0.4	5
574	Preoperative Fibrosis-4 (FIB-4) Evaluation May Be Helpful to Evaluate Prognosis of Gastric Cancer Patients Undergoing Operation: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 655343.	1.3	3

#	ARTICLE	IF	CITATIONS
575	PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 139-144.	0.3	9
576	Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. <i>World Journal of Gastroenterology</i> , 2021, 27, 3238-3248.	1.4	6
577	Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1833-1841.	0.2	15
578	Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. <i>Scientific Reports</i> , 2021, 11, 13616.	1.6	16
579	Prognostic significance of liver stiffness assessed by fibrosisâ€4 index in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 3809-3821.	1.4	9
580	The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 454-466.	0.8	24
581	Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer. <i>BMC Cancer</i> , 2021, 21, 798.	1.1	5
582	Usefulness of FibroScan-AST (FAST) score in Japanese patients with non-alcoholic fatty liver disease: A single-center retrospective experience. <i>Acta Hepatologica Japonica</i> , 2021, 62, 393-402.	0.0	0
583	Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. <i>Digestive and Liver Disease</i> , 2021, 53, 873-878.	0.4	2
584	Prognostic Value of Liver Stiffness Measured by Two-Dimensional Elastography in Acute Decompensated Heart Failure with Preserved Ejection Fraction. <i>International Heart Journal</i> , 2021, 62, 821-828.	0.5	3
585	Identifying Patients at Risk for Fibrosis in a Primary Care NAFLD Cohort. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	3
586	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.	1.4	36
587	Fibrosisâ€4 Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021, 5, 1605-1615.	2.0	9
588	Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab123.	0.1	3
589	Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108873.	1.1	9
590	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
591	Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. <i>PLoS ONE</i> , 2021, 16, e0254939.	1.1	7
592	Clinical Significance of the Fibrosis-4 Index in Patients with Acute Heart Failure Requiring Intensive Care. <i>International Heart Journal</i> , 2021, 62, 858-865.	0.5	7

#	ARTICLE	IF	CITATIONS
593	Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105788.	0.7	15
594	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1451-1458.	0.8	10
595	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
596	Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. <i>Gastroenterology Research</i> , 2021, 14, 244-251.	0.4	2
598	Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults. <i>Scientific Reports</i> , 2021, 11, 15647.	1.6	9
599	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1065-1078.	1.5	6
600	A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure. <i>Hepatology</i> , 2021, 74, 2974-2987.	3.6	4
601	Effect of 48-week pema fibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan aspartate aminotransferase score. <i>JGH Open</i> , 2021, 5, 1183-1189.	0.7	21
602	Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease. <i>Canadian Liver Journal</i> , 2021, 4, 275-282.	0.3	2
603	Close association between non-alcoholic fatty liver disease and ossification of the posterior longitudinal ligament of the spine. <i>Scientific Reports</i> , 2021, 11, 17412.	1.6	7
604	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8993.	1.2	10
605	Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease – implications for the clinical utility of the EASL NIT guideline. <i>Journal of Hepatology</i> , 2022, 76, 245-246.	1.8	12
606	Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. <i>Journal of Hepatology</i> , 2021, 75, 1284-1291.	1.8	229
607	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	2.9	28
608	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. <i>Diabetes and Metabolism</i> , 2022, 48, 101281.	1.4	5
609	Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. <i>Hepatology</i> , 2021, 74, 3472-3478.	3.6	21
610	Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14863.	0.8	2
611	Magnetic resonance elastography plus Fibrosis-4 versus FibroScan aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	3.6	29

#	ARTICLE	IF	CITATIONS
612	Thrombocytopenia Associated with Unrecognized Non-Alcoholic Fatty Liver Disease Is an Independent Predictor of Perioperative Significant Blood Loss in Cervical Laminoplasty. <i>World Neurosurgery</i> , 2021, 155, e797-e804.	0.7	0
613	Risk stratification of hepatocellular carcinoma in patients with chronic liver disease by combining gadolinium-ethoxybenzyl diethylenetriamine-pentaacetic acid-enhanced magnetic resonance imaging and magnetic resonance elastography. <i>GastroHep</i> , 2021, 3, 435-442.	0.3	1
614	Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 343-353.	1.1	0
615	Changing clinical management of NAFLD in Asia. <i>Liver International</i> , 2022, 42, 1955-1968.	1.9	18
616	Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 5753-5763.	1.4	21
617	Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. <i>Drug Metabolism and Disposition</i> , 2022, 50, 492-499.	1.7	5
618	A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 3-14.	2.2	56
619	Hepatic fibrosis of any origin in a large population of type 2 diabetes patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2887-2894.	1.1	5
620	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4
621	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 835-856.	8.2	183
622	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.6	229
623	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107978.	1.2	5
624	Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, G252-G261.	1.6	4
625	Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 69-77.	1.0	4
626	Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2172-2181.e6.	2.4	110
627	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	1.8	100
628	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. <i>Nutrients</i> , 2021, 13, 169.	1.7	9
629	Clinical significance of spleen stiffness in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> , 2020, 7, 4005-4014.	1.4	8

#	ARTICLE	IF	CITATIONS
630	Evaluation of Fibrosis in Intestinal Failure-Associated Liver Disease in the Sustain Registry. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 1285-1290.	1.3	1
631	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 417-440.	0.8	21
632	Non-alcoholic Fatty Liver Disease (NAFLD) and Bariatric Surgery. , 2016, , 629-636.		1
633	Non-invasive Serum Markers of Fibrosis. , 2018, , 63-82.		1
634	Work up of fatty liver by primary care physicians, review. <i>Annals of Medicine and Surgery</i> , 2020, 50, 41-48.	0.5	4
635	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2020, 40, .	1.1	21
636	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, 98-103.	0.8	33
637	Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 728-736.	1.9	104
638	Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. <i>International Journal of STD and AIDS</i> , 2021, 32, 266-275.	0.5	8
639	The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. <i>Medical Science Monitor</i> , 2012, 18, CR735-CR740.	0.5	46
640	NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. <i>PLoS ONE</i> , 2013, 8, e58360.	1.1	36
641	The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥ 10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals. <i>PLoS ONE</i> , 2015, 10, e0140427.	1.1	64
642	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	1.1	17
643	Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0240195.	1.1	14
644	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-11.	0.7	51
645	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.2	65
646	The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases. <i>Hepatology Forum</i> , 2020, , 8-13.	0.3	27
647	Evaluation of liver fibrosis: "Something old, something new". <i>Annals of Gastroenterology</i> , 2016, 29, 445-453.	0.4	36

#	ARTICLE	IF	CITATIONS
648	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	0.9	3
650	Ketogenic, hypocaloric diet improves nonalcoholic steatohepatitis. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 26-31.	1.0	9
651	Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. <i>Yonago Acta Medica</i> , 2020, 63, 188-197.	0.3	15
652	Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. <i>Korean Journal of Pediatrics</i> , 2013, 56, 45.	1.9	10
653	Non-Alcoholic Fatty Liver Disease and Its Association with Depression in Korean General Population. <i>Journal of Korean Medical Science</i> , 2019, 34, e199.	1.1	33
654	Recent research trends and updates on nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 1-11.	4.5	74
655	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 389.	1.5	2
656	Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1290.	1.7	20
657	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2021, 22, 40.	1.8	8
658	Noninvasive Parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 1525.	1.4	86
659	Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 7718.	1.4	25
660	Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. <i>World Journal of Gastroenterology</i> , 2014, 20, 10851.	1.4	93
661	Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?. <i>World Journal of Gastroenterology</i> , 2015, 21, 3223-3231.	1.4	33
662	Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia. <i>World Journal of Gastroenterology</i> , 2015, 21, 5893-5900.	1.4	26
663	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. <i>World Journal of Gastroenterology</i> , 2018, 24, 4835-4845.	1.4	31
664	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 5919-5943.	1.4	33
665	Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. <i>Endocrinology and Metabolism</i> , 2020, 35, 165.	1.3	30
666	Red complex periodontal pathogens are risk factors for liver cirrhosis. <i>Biomedical Reports</i> , 2019, 11, 199-206.	0.9	7

#	ARTICLE	IF	CITATIONS
667	Assessing liver fibrosis without biopsy in patients with HCV or NAFLD. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 179-186.	0.6	10
668	The value of noninvasive scoring systems for the diagnosis of advanced fibrosis in Egyptian patients with nonalcoholic fatty liver disease. <i>The Egyptian Journal of Internal Medicine</i> , 2014, 26, 162-169.	0.3	4
669	Non-invasive prediction of non-alcoholic steatohepatitis in Japanese patients with morbid obesity by artificial intelligence using rule extraction technology. <i>World Journal of Hepatology</i> , 2018, 10, 934-943.	0.8	11
670	Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. <i>World Journal of Hepatology</i> , 2010, 2, 374.	0.8	14
671	Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. <i>World Journal of Hepatology</i> , 2015, 7, 1586.	0.8	20
672	Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 2749.	0.8	15
673	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 638.	0.8	68
674	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. <i>World Journal of Hepatology</i> , 2015, 7, 1192.	0.8	8
675	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 486-491.	1.4	51
676	A Nomogram for Predicting Non-Alcoholic Fatty Liver Disease in Obese Children. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2020, 23, 276.	0.4	3
677	Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2021, 15, 1347-1355.	1.9	6
679	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17
680	Stratification by obesity class, rather than age, can identify a higher percent of children at risk for nonalcoholic fatty liver disease and metabolic dysfunction. <i>Pediatric Obesity</i> , 2022, 17, e12862.	1.4	7
681	A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. <i>Scientific Reports</i> , 2021, 11, 19992.	1.6	7
682	Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	1
683	A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. <i>BMC Geriatrics</i> , 2021, 21, 544.	1.1	5
684	The distribution of FIB-4 index in Japanese subjects undergoing a health checkup who are diagnosed as having nonalcoholic fatty liver disease. <i>Acta Hepatologica Japonica</i> , 2011, 52, 390-392.	0.0	3
685	The Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , 2014, 86, 405.	0.1	1

#	ARTICLE	IF	CITATIONS
689	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes, 2018, , 47-69.	0.0	0
690	Fibroscan and non-invasive indices for the diagnosis of nonalcoholic fatty liver disease. Gastroenterología, 2017, 51, 183-187.	0.0	0
691	Noninvasive Assessment of Disease Progression. , 2018, , 117-126.e3.		1
692	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease. , 2018, , 391-405.e3.		1
693	Diagnostic significance of biochemical indicators of liver fibrogenesis in adolescents with obesity. Ukrainian Biochemical Journal, 2019, 91, 74-79.	0.1	2
694	Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. , 2019, , 1-21.		0
695	Non-invasive methods for detection of progressive fibrosis in patients with nonalcoholic fat liver disease. Profilakticheskaya Meditsina, 2019, 22, 82.	0.2	2
696	Assessment of Liver Fibrosis Using Real Time Elastography and FIB 4 Score in Comparison to Liver Biopsy in Chronic HCV Egyptian Patients. The Egyptian Journal of Hospital Medicine, 2019, 74, 1836-1843.	0.0	1
697	RESEARCH ARTICLE SERUM SYNDECAN-1 AND APOLIPOPROTEIN A1 IN PATIENTS WITH CHRONIC HCV INFECTION. Sohag Medical Journal (SMJ), 2019, 23, 233-247.	0.1	0
698	Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population. Journal of Clinical and Translational Hepatology, 2019, 7, 1-5.	0.7	0
699	Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit. British Journal of Diabetes, 2019, 19, 118-123.	0.1	0
701	The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine, 2020, 1, .	1.5	6
702	TGF- β 1 & PNPLA3 Genetic Variants and the Risk of Hepatic Fibrosis and HCC in Egyptian Patients with HCV-Related Liver Cirrhosis. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3317-3326.	0.5	6
703	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
704	Noninvasive Biomarkers for Liver Fibrosis. , 2020, , 427-441.		0
705	Pediatric Liver Disease. , 2020, , 453-469.		0
707	Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. Choonpa Igaku, 2020, 47, 241-248.	0.0	0
708	LIVER MANIFESTATIONS IN COVID-19 AND THE INFLUENCE OF PRE-EXISTING LIVER DISEASE IN THE COURSE OF THE INFECTION. Revista Espanola De Enfermedades Digestivas, 2020, 113, 103-109.	0.1	10

#	ARTICLE	IF	CITATIONS
709	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. , 2020, , 225-234.		0
710	Ultrasound elastography in patients with fatty liver disease. Radiologia Brasileira, 2020, 53, 47-55.	0.3	16
711	Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. Biomedicines, 2021, 9, 1617.	1.4	2
712	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. International Journal of Molecular Sciences, 2021, 22, 11905.	1.8	34
713	Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease. Frontiers in Endocrinology, 2021, 12, 752944.	1.5	13
714	Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatology Research, 2022, 52, 176-186.	1.8	8
716	Diagnostic Assessment of Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine, 2020, 95, 299-307.	0.1	0
717	Non-invasive assessment of liver fibrosis. Annals of Gastroenterology, 2012, 25, 218-231.	0.4	93
718	Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterology and Hepatology, 2012, 8, 661-8.	0.2	30
720	Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterology and Hepatology, 2019, 15, 357-365.	0.2	10
721	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00417.	1.3	1
722	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00417.	1.3	13
723	Advances in Liver Rehabilitation. The Japanese Journal of Rehabilitation Medicine, 2021, 58, 1120-1127.	0.0	0
724	Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients. Dermatologic Therapy, 2022, 35, e15203.	0.8	4
725	Nonalcoholic Fatty Liver Disease Underdiagnosis in Primary Care: What Are We Missing?. Journal of General Internal Medicine, 2022, 37, 2587-2590.	1.3	5
726	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology, 2022, 76, 536-548.	1.8	66
727	Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. Journal of the Chinese Medical Association, 2022, 85, 152-159.	0.6	3
728	Evaluation of fibrosis in patients with nonalcoholic fatty liver disease. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2021, 87, 1-1.	0.1	0

#	ARTICLE	IF	CITATIONS
730	Fatty Liver Disease: Diagnosis and Stratification. Annual Review of Medicine, 2022, 73, 529-544.	5.0	17
731	Acoustic radiation force impulse elastography and liver fibrosis risk scores in severe obesity. Archives of Endocrinology and Metabolism, 2021, 65, .	0.3	3
732	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. JHEP Reports, 2022, 4, 100411.	2.6	24
733	Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. Endocrine Journal, 2022, 69, 463-471.	0.7	19
734	Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. European Endocrinology, 2021, 17, 112.	0.8	1
735	Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. Metabolism Open, 2022, 13, 100158.	1.4	8
736	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clinical and Experimental, 2022, 128, 154958.	1.5	18
737	An algorithm for the management of non-alcoholic fatty liver disease in primary care. Gastroenterology & Hepatology (Bartlesville, Okla), 2021, 12, 114-122.	0.0	0
738	The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. Journal of General Internal Medicine, 2022, 37, 3266-3274.	1.3	3
739	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 795-811.	1.4	21
740	Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 358-369.e12.	2.4	17
741	Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2022, 117, 453-461.	0.2	28
742	Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. Journal of Personalized Medicine, 2022, 12, 92.	1.1	6
743	A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 994-1007.	1.9	2
744	Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. Obesity Surgery, 2022, 32, 712-719.	1.1	4
745	Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection. International Journal of Clinical Oncology, 2022, 27, 717-728.	1.0	4
746	Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. Alimentary Pharmacology and Therapeutics, 2022, 55, 580-592.	1.9	12
747	Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. Scientific Reports, 2022, 12, 1062.	1.6	6

#	ARTICLE	IF	CITATIONS
748	Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	4
749	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 154-161.	0.6	24
750	Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. <i>Nutrients</i> , 2022, 14, 556.	1.7	10
751	Association of Physical Activity to Sarcopenia, Liver Fibrosis, and Cardiovascular Disease: Need a Closer Look!. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
752	Long-term prediction of hepatocellular carcinoma using serum autotaxin levels after antiviral therapy for hepatitis C. <i>Annals of Hepatology</i> , 2022, 27, 100660.	0.6	2
753	Advances in fibrosis biomarkers in nonalcoholic fatty liver disease. <i>Advances in Clinical Chemistry</i> , 2022, 106, 33-65.	1.8	5
754	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. <i>Diagnostics</i> , 2022, 12, 407.	1.3	22
755	Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. <i>Journal of Clinical Medicine</i> , 2022, 11, 878.	1.0	2
756	Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 435-444.e6.	2.4	25
758	FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. <i>BMC Gastroenterology</i> , 2021, 21, 453.	0.8	33
759	Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. <i>JMA Journal</i> , 2022, 5, .	0.6	1
760	The Concept of Indeterminable NASH Induced by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. <i>Biomedicines</i> , 2022, 10, 453.	1.4	2
761	Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting. , 2022, 33, 153-160.		3
762	Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. <i>Scientific Reports</i> , 2022, 12, 2538.	1.6	3
763	Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome. <i>Cureus</i> , 2022, 14, e22682.	0.2	1
764	“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”, <i>HIV Medicine</i> , 2022, 23, 911-921.	1.0	3
765	The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004. <i>Nutrients</i> , 2022, 14, 1224.	1.7	22
766	The useful predictors of zinc deficiency for the management of chronic liver disease. <i>Journal of Gastroenterology</i> , 2022, 57, 322-332.	2.3	5

#	ARTICLE	IF	CITATIONS
767	Association between Non-alcoholic Fatty Liver Disease and the Severity of Coronary Artery Stenosis in Eastern Chinese Population. <i>Hepatitis Monthly</i> , 2022, 21, .	0.1	2
768	Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2023, 69, .	0.3	5
769	Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure. <i>ESC Heart Failure</i> , 2022, 9, 1832-1843.	1.4	5
770	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	1.9	9
771	Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. <i>Postgraduate Medicine</i> , 2022, 134, 435-440.	0.9	13
772	Validation of type 2 diabetes subgroups by simple clinical parameters: a retrospective cohort study of NHANES data from 1999 to 2014. <i>BMJ Open</i> , 2022, 12, e055647.	0.8	5
773	Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1243-1251.e12.	2.4	32
774	Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003â€“2018): cross-sectional study. <i>BMJ Open</i> , 2022, 12, e058517.	0.8	4
775	Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. <i>EClinicalMedicine</i> , 2022, 46, 101325.	3.2	8
776	Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. <i>BMC Public Health</i> , 2022, 22, 655.	1.2	4
777	Fibrosisâ€“4 Index as an Independent Predictor of Mortality and Liverâ€“Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	2.0	26
778	Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2790-2799.e4.	2.4	21
779	Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 773342.	1.5	6
780	Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. <i>Diagnostics</i> , 2021, 11, 2316.	1.3	8
781	Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e986-e991.	0.8	6
782	Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. <i>Frontiers in Endocrinology</i> , 2021, 12, 777075.	1.5	8
783	Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. <i>World Journal of Hepatology</i> , 2021, 13, 2179-2191.	0.8	3
784	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approachâ€“the institutional adaptation to existing Clinical Practice Guidelines. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 12-22.	0.1	2

#	ARTICLE	IF	CITATIONS
785	Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis. <i>Digestive Diseases</i> , 2022, 40, 734-744.	0.8	10
786	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	6.1	57
787	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	1.8	27
788	High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	8
789	Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study. <i>International Journal of Circumpolar Health</i> , 2022, 81, 2065755.	0.5	3
790	Prognosis of chronic kidney disease in patients with non-alcoholic fatty liver disease: a Northeastern Taiwan community medicine research cohort. <i>Biomedical Journal</i> , 2023, 46, 100532.	1.4	4
791	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€”Occamâ€™s razor applied to advanced fibrosis screening. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1759-1760.	1.9	7
792	Liver Fibrosisâ€4 index indicates atrial fibrillation in acute ischemic stroke. <i>European Journal of Neurology</i> , 2022, 29, 2283-2288.	1.7	5
793	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 755-769.	3.7	34
794	Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5035.	1.8	2
795	Prevalence and Prognostic Importance of High Fibrosis-4 Index in COVID-19 Patients. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-8.	0.8	3
796	Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. <i>Hepatology Communications</i> , 2022, 6, 2238-2252.	2.0	11
797	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5146.	1.8	22
798	Clinical utility of computed tomography-based evaluation of trunk muscles in primary sclerosing cholangitis. <i>Japanese Journal of Radiology</i> , 2022, , .	1.0	1
799	Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity. <i>Eating and Weight Disorders</i> , 2022, 27, 2617-2627.	1.2	1
800	Medical checkup data analysis method based on LiNGAM and its application to nonalcoholic fatty liver disease. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102310.	3.8	2
801	Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. <i>BMC Gastroenterology</i> , 2022, 22, 241.	0.8	13
802	<sc>FIB</sc>â€4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: A <sc>Fineâ€Gray</sc> competing risk analysis. <i>Liver International</i> , 2023, 43, 170-179.	1.9	9

#	ARTICLE	IF	CITATIONS
803	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. <i>Journal of Hepatology</i> , 2022, 76, 1362-1378.	1.8	78
804	A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. <i>PLoS ONE</i> , 2022, 17, e0269265.	1.1	10
805	Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1013-1022.e6.	2.4	12
806	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	0.9	12
808	Risk factors for Fontan-associated hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0270230.	1.1	12
809	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	8
810	Association between liver fibrosis and incident dementia in the <sc>UK</sc> Biobank study. <i>European Journal of Neurology</i> , 2022, 29, 2622-2630.	1.7	13
811	Letter: noninvasive prediction models to exclude cirrhosis in <sc>NAFLD</sc> â€” not everyone fits the mould. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 182-183.	1.9	0
812	Combinational elastography for assessment of liver fibrosis in patients with liver injury. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211001.	0.4	3
813	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	6.1	82
814	Patient-centered care: Key elements applicable to chronic liver disease. <i>Hepatology</i> , 2023, 78, 307-318.	3.6	0
815	Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. <i>Hepatology Communications</i> , 2022, 6, 2227-2237.	2.0	15
816	Prognostic importance of improving hepatorenal function during hospitalization in acute decompensated heart failure. <i>ESC Heart Failure</i> , 0, , .	1.4	2
817	One-hour post-load glucose is associated with severity of hepatic fibrosis risk. <i>Diabetes Research and Clinical Practice</i> , 2022, 189, 109977.	1.1	9
818	Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 3243-3257.	1.4	16
819	Nonalcoholic Fatty Liver Disease and Risk of Early-Onset Vasomotor Symptoms in Lean and Overweight Premenopausal Women. <i>Nutrients</i> , 2022, 14, 2805.	1.7	0
820	Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101997.	0.7	7
821	Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes. <i>International Journal of Hypertension</i> , 2022, 2022, 1-8.	0.5	2

#	ARTICLE	IF	CITATIONS
822	Abdominal aortic calcification is associated with Fibrosisâ€4 index and low body mass index in typeâ€2 diabetes patients: A retrospective crossâ€sectional study. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1861-1872.	1.1	1
823	Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 3039.	1.7	12
824	Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia. <i>Biomedicines</i> , 2022, 10, 1770.	1.4	7
825	Gut Microbiotaâ€A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8307.	1.8	9
826	Association of serum creatinine with hepatic steatosis and fibrosis: a cross-sectional study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	2
827	Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. <i>Journal of Clinical Medicine</i> , 2022, 11, 4394.	1.0	3
828	Xanthine oxidoreductase activity is correlated with hepatic steatosis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
829	The fibrosisâ€4 score is associated with longâ€term mortality in different phenotypes of acute heart failure. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	2
830	Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI. <i>Clinical Research in Cardiology</i> , 2023, 112, 236-246.	1.5	5
831	Prevalence of sarcopenia using different methods in patients with non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 1643-1651.	0.8	4
832	Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S51-S58.	0.1	3
833	Association between metabolically healthy obesity and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2022, 16, 1412-1423.	1.9	10
834	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample. <i>Hepatology Research</i> , 2022, 52, 908-918.	1.8	6
835	Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 1633-1642.	0.8	3
836	Transient Elastography and Serum-Based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort: A Cross-Sectional Analysis. <i>Digestive Diseases</i> , 2023, 41, 767-779.	0.8	4
837	Noninvasive Fibrosis Screening in Fatty Liver Disease Among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 Score Accuracy. <i>Diabetes Care</i> , 2022, 45, 2449-2451.	4.3	3
838	Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2839-2847.	1.1	3
839	Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease- related hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
840	An affordable approach to classifying type 2 diabetes based on fasting plasma glucose, TyG index and BMI: a retrospective cohort study of NHANES Data from 1988 to 2014. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
841	Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor. , 2022, 1, 1108-1113.		1
842	Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. <i>Children</i> , 2022, 9, 1174.	0.6	5
843	Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 1409-1417.	2.2	5
844	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Choonpa Igaku</i> , 2022, 49, 385-396.	0.0	0
845	The Change in the Fibrosis-4 Index for the Assessment of Liver Fibrosis After Pancreaticoduodenectomy. <i>Pancreas</i> , 2022, 51, 624-627.	0.5	0
846	Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. <i>Hepatology Communications</i> , 2022, 6, 3073-3082.	2.0	14
847	Hepatic Fibrosis Is a Risk Factor for Greater Severity and Worse Outcome of Acute Ischemic Stroke. <i>Journal of Clinical Medicine</i> , 2022, 11, 5141.	1.0	2
848	Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study. <i>Metabolites</i> , 2022, 12, 893.	1.3	1
849	Analysis of time-dependent changes in the FIB4 index in patients with obesity receiving weight reduction therapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
850	Gastrointestinal and Liver Complications in Patients with Diabetes Mellitusâ€”A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 5223.	1.0	5
852	Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2023, 118, 95-104.	0.2	2
853	Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. <i>Hepatology Communications</i> , 2022, 6, 3024-3035.	2.0	1
855	Liver steatosis and fibrosis markersâ€™ association with cardiovascular and renal damage in Japanese adults: the TMM BirThree cohort study. <i>Annals of Hepatology</i> , 2022, , 100761.	0.6	2
856	Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease â€” a survey in a university hospital in Brazil. <i>Archives of Endocrinology and Metabolism</i> , 2022, , .	0.3	0
857	Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in Obese Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. <i>Cureus</i> , 2022, , .	0.2	0
858	Machine learning models including insulin resistance indexes for predicting liver stiffness in United States population: Data from NHANES. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
859	Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10

#	ARTICLE	IF	CITATIONS
860	N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. <i>Hepatology International</i> , 2023, 17, 190-201.	1.9	6
861	Candidate screening for heart failure with preserved ejection fraction clinic by Fib-4 index from subclinical subjects. , 2022, , .		1
862	Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
863	Transitional phase Gd-EOB-DTPA-enhanced MRI: visual assessment of hepatic function and fibrosis based on uptake rate of Gd-EOB-DTPA. <i>European Journal of Radiology</i> , 2022, , 110550.	1.2	0
865	Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	0.9	1
867	Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 4222.	1.7	2
869	A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
870	Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers. <i>Hepatology Communications</i> , 2022, 6, 3299-3310.	2.0	6
871	High Preoperative Fibrosis-4 Index Is Associated With Postoperative Mortality: An Argument to Look for Advanced Liver Disease Before Surgery. <i>Anesthesia and Analgesia</i> , 2022, 135, 954-956.	1.1	0
872	Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
873	New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD. <i>Annals of Hepatology</i> , 2023, 28, 100774.	0.6	4
874	Identification of a Fatty Acid for Diagnosing Non-Alcoholic Steatohepatitis in Patients with Severe Obesity Undergoing Metabolic Surgery. <i>Biomedicines</i> , 2022, 10, 2920.	1.4	2
875	Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2022, 17, e0277380.	1.1	0
876	ALT is not associated with achieving subcirrhotic liver stiffness and HCC during entecavir therapy in HBV-related cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	1
877	Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2023, 78, 493-500.	1.8	20
878	Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers. <i>Metabolites</i> , 2022, 12, 1073.	1.3	1
879	Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 709-722.	1.9	13
880	Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023, 14, 260-269.	2.9	4

#	ARTICLE	IF	CITATIONS
881	Aging affects FIB-4 index in the general population without pre-existing diseases: Analysis of a cohort of healthy individuals who underwent annual health checkups for 10 consecutive years. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102058.	0.7	1
882	Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 108-118.	3.0	9
883	Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	9
884	Assessment of Visceral Fat Volume and Its Correlation with the Severity of Hepatic Fibrosis in Patients with NAFLD. <i>Journal of the Association of Physicians of India</i> , The, 2022, 70, 23-24.	0.0	0
885	Association between History of Pregnancy and Liver Fibrosis Using Fibrosis-4 Index in Korean Postmenopausal Women: A Nationwide Population-Based Study. <i>Korean Journal of Family Medicine</i> , 2022, 43, 388-395.	0.4	0
886	Nonalcoholic fatty liver disease (NAFLD) among older adults. , 2022, 1, 184-191.		0
887	Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
888	HÃgado graso: una epidemia silente. , 2022, 44, 386-395.		0
889	Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study. <i>PLoS ONE</i> , 2022, 17, e0277930.	1.1	1
890	Assessment of Liver Dysfunction Using Combination Biomarkers in Children Living with HIV Infection. <i>Journal of Pediatric Research</i> , 2022, 9, 368-375.	0.1	0
891	Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102679.	1.8	3
892	SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. <i>Journal of Gastroenterology</i> , 2023, 58, 79-97.	2.3	6
893	Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7213.	1.0	1
894	Risk Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Non-Obese Patients with Obstructive Sleep Apnea. <i>Nature and Science of Sleep</i> , 0, Volume 14, 2143-2149.	1.4	0
895	Liver fibrosis and retinal features in an older Mediterranean population: Results from the Salus in Apulia study. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	3
896	Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. <i>PLoS ONE</i> , 2022, 17, e0277729.	1.1	5
897	Greenlight laser (XPSTM) 180W prostatectomy for treatment of benign prostate hyperplasia in patients with uncorrectable bleeding tendency. <i>Arab Journal of Urology Arab Association of Urology</i> , 2023, 21, 129-134.	0.7	0
898	Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	5

#	ARTICLE	IF	CITATIONS
900	Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. <i>Annals of Hepatology</i> , 2023, 28, 100892.	0.6	2
901	Preoperative circulating peroxiredoxin 1 levels as a predictor of non-alcoholic fatty liver disease remission after laparoscopic bariatric surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
902	Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1032-1044.	2.2	10
903	Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia. <i>Liver International</i> , 2023, 43, 413-423.	1.9	8
904	Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	2
905	Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1
906	The Risk of Endoscopy-Related Bleeding in Patients with Liver Cirrhosis: A Retrospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 170.	0.8	0
907	Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2023, 7, e0016-e0016.	2.0	5
908	Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study. <i>BMJ Open</i> , 2023, 13, e063959.	0.8	0
909	Leveraging the South African Diabetes Prevention Programme to screen for chronic kidney disease: an observational study. <i>BMJ Open</i> , 2023, 13, e068672.	0.8	3
910	Liver fibrosis for the dermatologist: a review. <i>Clinical and Experimental Dermatology</i> , 0, , .	0.6	1
911	Validation of the Hepamet fibrosis score in a multi-ethnic Asian population. <i>Annals of Hepatology</i> , 2023, 28, 100888.	0.6	2
912	The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. <i>Nutrients</i> , 2023, 15, 66.	1.7	5
913	Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?. <i>Diagnostics</i> , 2023, 13, 91.	1.3	8
914	Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. <i>Hepatology International</i> , 2023, 17, 606-614.	1.9	8
915	Screening for MAFLD: who, when and how?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2023, 14, 204201882211456.	1.4	5
916	Liver cirrhosis: relationship between fibrosis-associated hepatic morphological changes and portal hemodynamics using four-dimensional flow magnetic resonance imaging. <i>Japanese Journal of Radiology</i> , 2023, 41, 625-636.	1.0	2
917	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. <i>Nutrients</i> , 2023, 15, 687.	1.7	12

#	ARTICLE	IF	CITATIONS
919	Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 104-117.	1.8	6
921	The Link between NAFLD and Metabolic Syndrome. <i>Diagnostics</i> , 2023, 13, 614.	1.3	10
922	Serum Fatty Acid Composition Balance by Fuzzy C-Means Method in Individuals with or without Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Nutrients</i> , 2023, 15, 809.	1.7	0
923	Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108475.	1.2	2
924	Basic assessment on adding platelet measurement to legal health checkup in Japan: A cross-sectional and 20-year longitudinal study. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
925	Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. <i>Hepatology Communications</i> , 2023, 7, e0024-e0024.	2.0	1
926	Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. <i>Nutrients</i> , 2023, 15, 748.	1.7	2
927	Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 783-793.	0.4	3
928	Dynapenia, Muscle Quality, and Hepatic Steatosis in Patients with Obesity and Sarcopenic Obesity. <i>Biomedicines</i> , 2023, 11, 472.	1.4	0
929	Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	6
930	Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 375.	0.8	1
931	Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	0
932	Real-World Primary Care Data Comparing ALT and FIB-4 in Predicting Future Severe Liver Disease Outcomes. <i>Journal of General Internal Medicine</i> , 2023, 38, 2453-2460.	1.3	0
933	Liver fibrosis-4 score predicts outcome of patients with ischemic stroke undergoing intravenous thrombolysis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	3
934	Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 14, 13-27.	1.1	0
935	Fibrosis-4 index identifies worsening renal function associated with adverse outcomes in acute heart failure. <i>ESC Heart Failure</i> , 0, , .	1.4	2
936	Noninvasive assessments of liver disease severity based on biomarkers. , 2023, , 31-60.		0
937	The Prevalence of Advanced Liver Fibrosis among Patients with Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2023, 38, 52-61.	0.1	1

#	ARTICLE	IF	CITATIONS
938	The utility of noninvasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis. <i>Liver International</i> , 2023, 43, 1008-1014.	1.9	1
939	Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis. <i>Journal of Medical Economics</i> , 2023, 26, 348-356.	1.0	1
940	Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2889-2900.e10.	2.4	3
941	Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2023, 15, 1659.	1.7	3
942	Computerized Tomography-Based Screening for Moderate to Severe Hepatic Steatosis in a Multiethnic Population. , 2023, 27, 21-27.		1
943	Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study. <i>Biomedicines</i> , 2023, 11, 869.	1.4	3
944	Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 0, , .	1.3	1
945	The Association between Advanced Liver Fibrosis and Mortality Is Modified by Dietary Quality among Korean Adults: Results from the Korea National Health and Nutrition Examination Survey with Mortality Data. <i>Nutrients</i> , 2023, 15, 1501.	1.7	0
946	Hígado graso (parte 2): enfoque clínico y tratamiento. <i>Revista Colombiana De Gastroenterología</i> , 2023, 38, 46-58.	0.1	0
947	ABDA Score: A Non-invasive Model to Identify Subjects with Fibrotic Non-alcoholic Steatohepatitis in the Community. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 742-752.	0.4	0
948	Liver injury indicators and subsequent cancer development among nonfatty liver population. <i>Cancer Medicine</i> , 2023, 12, 12173-12186.	1.3	2
949	Fatty Liver Disease. , 2024, , 330-401.		1
950	Multiparametric MR assessment of liver fat, iron, and fibrosis: a concise overview of the liver "Triple Screen". <i>Abdominal Radiology</i> , 2023, 48, 2060-2073.	1.0	1
951	The systemic immune-inflammation index was non-linear associated with all-cause mortality in individuals with nonalcoholic fatty liver disease. <i>Annals of Medicine</i> , 2023, 55, .	1.5	13
952	High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2858.	1.0	1
953	Clinical and prognostic implications of hyaluronic acid in hospitalized patients with heart failure. <i>Heart and Vessels</i> , 2023, 38, 1130-1137.	0.5	0
954	How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography? A Review of the Literature and Proposed Multistep Approach. <i>Diagnostics</i> , 2023, 13, 788.	1.3	7
970	Reply: Modeling concerns. <i>Hepatology</i> , 2023, 78, E41-E42.	3.6	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------